Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic…
Waltz Health, a digital health company developing smarter, technology-enabled ways to price, distribute and prescribe medications and Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people…
VSee Health, Inc. (Nasdaq: VSEE), a leading provider of telehealth services that optimize workflow and enhance patient care, has launched a new program to address obesity and related health risks…
NUCLIDIUM today announced the successful imaging of the first patient in a Phase 1 clinical trial evaluating its radiotracer candidate as a safe and effective diagnostic and disease-staging tool in…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225…
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases,…
Catalent Affirms Commitment to Customers and Patients Amidst Novo Holdings Acquisition Alessandro Maselli to Remain President and CEO of Catalent Post-Acquisition Catalent, Inc. (NYSE: CTLT), a leader in the development…
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® in First-Line Treatment of Gastric, Gastroesophageal, and Esophageal Cancers BeiGene, a global oncology leader, has achieved a significant milestone with the European Medicines…
Bruker Unveils Groundbreaking $100 Plasma Proteomics Platform, Pioneering Advances in Glycoproteomics and Metaproteomics Bruker Corporation has announced a revolutionary leap in 4D-Proteomics™, offering deep, high-fidelity plasma proteomics for just $100…
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study of ⁶¹Cu Radiotracer for Prostate Cancer NUCLIDIUM has successfully imaged the first patient in its Phase 1 clinical trial evaluating ⁶¹Cu-NuriPro™…
bioAffinity Technologies Announces $2.66 Million Registered Direct Offering and Concurrent Private Placement bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to developing noninvasive tests for early-stage cancer detection,…
Biological Lattice Industries Corp. (BLI), an innovator in biofabrication and life sciences, has closed a $1.8 million pre-seed funding round led by Greek venture capital firm Uni.Fund. Alongside this investment,…